Cystic Fibrosis Clinical Trial
Official title:
Effects of an Individualized and Partially Supervised Exercise Program on Parameters of Physical Fitness, Lung Function, Habitual Physical Activity in Daily Life and Quality of Life in Children, Adolescents and Adults With Cystic Fibrosis.
The aim of this study is to evaluate the effects of a partially supervised exercise program on different aspects of physical fitness, despite VO2peak, lung function, quality of life and sleep quality in children, adolescents and adults with Cystic Fibrosis.
There is growing consensus that exercise in subjects with cystic fibrosis (CF) may yield
improvements in measures of physical fitness, lung function and quality of life. In most of
the training studies exercise capacity was expressed as peak oxygen uptake (VO2peak), which
has been found to be one of the best predictors of survival in subjects with CF. Those
subjects with a higher VO2peak related to age and gender specific predicted VO2peak (%pred)
have a better prognosis than those with a lower VO2peak (%pred). VO2peak represents the
cardiorespiratory endurance is one aspect of physical fitness.
Physical fitness may be subdivided into health-related fitness and skill/performance-related
fitness. Cardiorespiratory endurance, muscular strength and endurance, body composition and
flexibility are often referred to as health-related fitness. Balance, coordination, speed,
agility and power are often described as skill/performance related fitness, reflecting the
performance aspect of physical fitness. It has been shown, that children and adolescents with
a lower skill / performance related fitness are less physical active than those with a higher
skill/performance related fitness. This may lead to physically inactive in daily life, less
motivation to take part in organized sport and as a consequence to a lower VO2peak.
The primary outcome parameters of this study is to evaluate the effects 12-month partially
supervised exercise program on 1) health-related fitness (endurance expressed as maximal
workload, muscular strength) and skill / performance related fitness (balance, power,
agility)and 2) habitual physical activity (steps / day; intensity expressed in METs) in a
large group of subjects with CF. Secondary outcome parameters include forced exspiratory
volume in 1 second (FEV1), sleep-wake cycle, quality of sleep, quality of life, and exercise
related barriers and barrier management in physical exercise.
In total 100 subjects with CF 6 year and older will be included. Habitual physical activity
and sleep will be recorded by accelerometer before subjects enter the exercise program, and
after 6 month and after 12 month. Check-ups, lung function measurement and testing of
physical fitness will be performed at baseline, after 6 and 12 month.
During the first six month the participants will be contacted by telephone every two weeks.
After six month individual counseling by telephone will be stopped.
The exercise program is planned as a "low-threshold exercise program "with low barriers to
participate. Participants will be asked about their interests and preferences of sports
activities to conceive the exercise program together with the participants. Along with
counseling participants will be motivated to increase physical activity by at least 10-20
minutes per day.
The investigators expect to gain another insight into different aspects of physical fitness,
habitual physical activity and sleep from the results of this study. Up to know, there are
only a few trails investigated different aspects of physical fitness that means balance,
flexibility, power as parameters of health-related fitness and skill/performance-related
fitness. The investigators assume that participants with higher values are more physical
active than those with lower values and these participants will have a higher
cardiorespiratory endurance.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |